Guide-yakabatana mibvunzo · Pakati Nhanho

AI muClinical Trials Quiz

Ongorora kuti AI inotsigira sei kuenzanirana kwemurwere, dhizaini yekuyedza, zvidzidzo zvinochinjika, kutarisa kwekuchengetedza, uye kusimbiswa kwemutemo mukutsvagisa kwekiriniki.

Nzira dzekutungamira dzinoenderanaAI Mukiriniki Miedzo
Mubvunzo 1 ye 8

Nderipi dambudziko renguva refu mumakiriniki ekuedzwa rinonyanya kunanga neAI?

Tarisa mubvunzo wese8 mibvunzo

Mhinduro uye tsananguro zvinoonekwa paunenge uchitora bvunzo.

  1. Nderipi dambudziko renguva refu mumakiriniki ekuedzwa rinonyanya kunanga neAI?
    • Kunonoka uye kwakaoma kutora varwere
    • Ruvara rwemishonga yekuputira
    • Mamenu ekudyira kuchipatara
    • Kuwanika kwekupaka panzvimbo dzekuyedza
  2. How can natural-language processing help screen patients for clinical trials?
    • Nekudarika kuongororwa kwekuchengetedza
    • Extract clinical information from electronic health records and compare it with trial eligibility criteria
    • Nokubhadhara varwere kupfuura vakwikwidzi
    • Nekupfupisa kutongwa kusvika kune rimwe zuva
  3. What is an external control arm in a clinical trial?
    • Robhoti prosthetic nhengo
    • Mushonga unogadzirwa nekombiyuta
    • A comparison group drawn from data outside the trial, such as historical or concurrent external data
    • A backup data server
  4. What can propensity-score matching do when constructing an external-control comparison?
    • Kuronga nearufabheti
    • Random nhamba yechizvarwa chete
    • Kuongorora zviperengo
    • Balance measured baseline covariates related to treatment assignment
  5. Sei fungidziro yekudonha uye saiti-kuita modhi zvine basa kune vanotsigira miedzo?
    • Vanorega vatsigiri vapindira pamberi pematare edzimhosva
    • Ivo vanogadzira chivakwa chekuvaka
    • Vanonyora masirogani ekutengesa
    • Vanosarudza yunifomu yevashandi
  6. What does FDA’s January 2025 draft AI guidance address for drugs and biologics?
    • Kuderedza tsvakurudzo yose zvachose
    • AI used to generate information supporting regulatory decisions about safety, effectiveness, or quality
    • Nekuti AI haisi pamutemo mukurapa
    • Kuderedza nhamba yevanachiremba
  7. What can a Bayesian adaptive clinical-trial design change as evidence accumulates?
    • The original trial question after results are known
    • The identity of past participants
    • Trial elements such as dosing or allocation to study arms under prespecified rules
    • The inclusion criteria without documentation
  8. Which pharmacovigilance tasks does FDA identify as possible uses for emerging AI?
    • Only advertising click-through rates
    • Satellite images of clinical sites
    • Unrelated social-media sentiment about packaging
    • Adverse-event intake, data entry, processing, and safety-signal detection or evaluation